Irbesartan + Hidroclorotiazida Sandoz (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide, the diuretic component, inhibits sodium‑chloride reabsorption in the distal tubule, promoting water loss and decreasing plasma volume. Together they provide complementary mechanisms to lower blood pressure.

The specific dose is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Healthcare professionals adjust the dosage to achieve optimal blood‑pressure control while monitoring safety.

The product is classified as Pregnancy Category D, indicating evidence of risk to the fetus and it should not be used during pregnancy. Safety during breastfeeding has not been established, and a healthcare provider should be consulted before use in nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with monotherapy agents, the Irbesartan/Hydrochlorothiazide combination offers dual action—vascular relaxation from the ARB and diuresis from the thiazide—often achieving better blood‑pressure control at lower individual doses. This can reduce pill burden versus separate prescriptions, though individual response and tolerance vary.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

The medication is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe hypotension, acute kidney injury, hyperkalemia, and rare cases of angioedema. Patients should be monitored for signs of these conditions, especially when initiating therapy or when combined with other drugs that affect renal function or electrolyte balance.

The combination is contraindicated in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. It should also be avoided in pregnant women and in individuals with severe renal impairment or anuria.